NEWS
View news from our Featured Companies.
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
PORTLAND, Maine, May 16, 2023 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
Scientific Industries Reports Financial Results for First Quarter of Fiscal Year 2023
BIOPROCESSING OPS ON TARGET WITH PRODUCT DEVELOPMENT AND COMMERCIALIZATIONBENCHTOP LAB EQUIPMENT OPS POSTS HIGHER SALES AND PROFITSNEW VIVID PLUS SUBSCRIPTION SERVICE GOES LIVEInvestor Call to be held Tuesday, May 16th at 11:00 a.m. Eastern TimeBOHEMIA, NY / May 16,...
Modular Medical Announces Pricing of Upsized $9.4 Million Public Offering
SAN DIEGO, CA / May 16, 2023 / Modular Medical, Inc. (the "Company" or "Modular Medical") (Nasdaq:MODD), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today...
Precision Optics Reports Third Quarter Fiscal Year 2023 Financial Results
Conference Call Scheduled for today, May 15, 2023 at 5:00pm ET GARDNER, Mass., May 15, 2023 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced...
SenesTech to Participate at Lytham Partners Spring 2023 Investor Conference on May 18, 2023
PHOENIX, May 15, 2023 -- SenesTech, Inc. (NASDAQ: SNES) (www.senestech.com) the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest®, today announced Joel Fruendt, CEO, will participate in a...
Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights
- Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 - - Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model - -...
Precision Optics Announces $1.5 Million Follow-On Product Development Order for Single Use Urology Program
GARDNER, Mass., May 12, 2023 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the receipt of a follow-on product development order for a...
Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
CUPERTINO, Calif., May 12, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Scientific Industries to Report First Quarter 2023 Financial Results on May 15, 2023
Investor Call to be held Tuesday, May 16th at 11:00 AM Eastern TimeBOHEMIA, NY / May 11, 2023 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, announced today it will file a Form...
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
Total prescriptions increased 32% compared to Q3 2022 to highest level in Company historyCompany to host conference call today at 4:30pm ETENGLEWOOD, CO / May 11, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023
PORTLAND, Maine, May 11, 2023 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
SenesTech Announces First Quarter 2023 Financial Results
E-Commerce Leads Growth at 54% Year Over Year PHOENIX, May 11, 2023 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female...
S&W Looks to Unlock Value of International Operations
LONGMONT, Colo., May 11, 2023 -- S&W Seed Company (Nasdaq: SANW), a global agricultural company, today announced that its Board of Directors is evaluating potential avenues to unlock what the Company sees as unrecognized value in its international operations,...
LiqTech International Announces First Quarter 2023 Financial Results
BALLERUP, Denmark, May 11, 2023 -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the first quarter of 2023 for the...
S&W Announces Third Quarter Fiscal 2023 Financial Results
LONGMONT, Colo., May 11, 2023 -- S&W Seed Company (Nasdaq: SANW) today announced financial results for the three months ended March 31, 2023. Q3 2023 Financial and Recent Highlights Revenue for the third quarter of fiscal 2023 was $17.7 million, a 23.8% decrease...
Mogo Reports Results for Q1 2023
Q1 2023 Revenue of $15.9 million and Gross Profit of $11.9 million Q1 2023 operating expenses down 45% year over year, driving positive Adjusted EBITDA of $1.0 million in the quarter Ended quarter with $60.4 million of cash and total investments1 Mogo reports in...
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023...
Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data
Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model IND submission for brilaroxazine lipogel in psoriasis expected in 2024 Reviva has filed composition of matter...
ChromaDex Corporation Reports First Quarter 2023 Financial Results
Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.9 million and $0.1 million, respectively, for the three months ended March 31, 2023. LOS ANGELES - ChromaDex Corp....
Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update
PONTE VEDRA, Fla., May 10, 2023 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in...
IRADIMED CORPORATION Named a 2023 Best Small Company in America by Forbes
WINTER SPRINGS, Fla., May 10, 2023 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), was recently named on Forbes' latest list of America's Best Small Companies for 2023. Iradimed is a leader in the development of innovative magnetic resonance imaging ("MRI")...
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections; Recruitment Expected to Resume Imminently Received Advice from the Swedish Medical Products Agency Consistent with...
Precision Optics Corporation Schedules Third Quarter of Fiscal Year 2023 Conference Call for Monday, May 15, 2023
GARDNER, Mass., May 9, 2023 -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that it has scheduled a conference call to...
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference
PONTE VEDRA, Fla., May 9, 2023 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, announced today that Quang Pham, CEO, will...
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
Encinitas, California--(May 9, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis...